EOLS News and Press, Evolus Inc. From 06/10/25

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse ™ Recognized as the Best Filler for 2025 with its recently...

2025-05-27 16:32:06 ET Read the full article on Seeking Alpha For further details see: Evolus announces CFO resignation

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellnes...

Data showed that both Evolysse ™ Form and Evolysse ™ Smooth met the primary endpoint of non-inferiority 1 and demonstrated statistical superiority 1 to Restylane ® -L, the control product The study published in Aesthetic Surgery Journal supports long...

2025-05-07 19:14:13 ET More on Evolus Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript Evolus: Two-Product Aesthetics Company With A Competitive Edge Evolus, Inc. 2024 Q4 - Results - Earnings Call Presentation Evolus announces commercial launch of Evolyss...

2025-05-07 19:13:09 ET Evolus, Inc. (EOLS) Q1 2025 Earnings Conference Call May 07, 2025 04:30 PM ET Company Participants Nareg Sagherian - VP, Head of Global IR and Corporate Communications David Moatazedi - President and CEO Sandra Beaver - CFO Conference...

2025-05-07 16:10:50 ET More on Evolus Evolus: Two-Product Aesthetics Company With A Competitive Edge Evolus, Inc. 2024 Q4 - Results - Earnings Call Presentation Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript Evolus announces commercial launch of Evolyss...

Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Ach...

BGSF Inc. (BGSF) is expected to report $-0.11 for Q1 2025 Veeco Instruments Inc. (VECO) is expected to report $0.16 for Q1 2025 Bruker Corporation (BRKR) is expected to report $0.46 for Q1 2025 Coeur Mining Inc. (CDE) is expected to report $0.02 for Q1 2025 LifeStance Health Group...

2025-05-06 17:20:54 ET More on Evolus Evolus: Two-Product Aesthetics Company With A Competitive Edge Evolus, Inc. 2024 Q4 - Results - Earnings Call Presentation Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript Evolus announces commercial launch of Evolyss...